Digital Cognitive

Screening










Diabetes and Memory

DTC’s NeuroTrack  Digital Cognitive Assessment (DCA) and screeing platform is an FDA Registered, patient-administered tool designed to help medical providers quickly and accurately distinguish cognitive impairment from normal aging. This fast, non-invasive solution delivers instant, objective results while seamlessly integrating into existing clinical workflows. Available for both in-clinic and remote testing, it ensures accessibility and convenience for diverse patient populations.

Eligible for reimbursement by Medicare and commercial insurance, NeuroTrack supports early detection and intervention for dementia and Alzheimer’s, helping providers enhance patient care while generating new revenue streams.

Bring Reimbursable, Cutting-Edge Cognitive Screening to Your Practice

The 3-minute cognitive screening can seamlessly extend into a comprehensive 10-minute assessment accessible on a computer, tablet, or smartphone, providing deeper insights into cognitive health with convenience and flexibility.

Cognitive Assessment

19:06 Minutes

Note: 15 second audio delay after pressing play. 

Listen and Discover

Empowering PCPs in Dementia Prevention & Early Detection

Dementia is a growing public health concern, with Alzheimer’s disease affecting nearly one in nine adults over 65 in the U.S.. In primary care, the early signs of cognitive decline often present as mild cognitive impairment (MCI)—subtle but measurable deficits in memory, thinking, and decision-making. PCPs play a critical role in early identification, intervention, and risk reduction, helping patients optimize brain health before significant cognitive deterioration occurs.

Genetics, Lifestyle, and Modifiable Risk Factors

While genetics and family history influence cognitive decline, modifiable lifestyle factors significantly impact dementia risk. PCPs can guide patients in managing key risk factors, which include:

Cholesterol and Cognitive Decline

Recent studies highlight a strong link between cholesterol levels and cognitive health. High LDL ("bad") cholesterol and low HDL ("good") cholesterol contribute to brain plaque formation, reduced cerebral blood flow, and neuroinflammation. Addressing lipid management early can be a proactive strategy for dementia prevention in at-risk patients.

The PCP’s Role in Early Intervention

Since dementia progresses over decades, early action is key. PCPs can integrate cognitive screening into routine care to identify risk factors early and guide prevention strategies. Key interventions include:

The Value of Cognitive Screening in Primary Care

By incorporating evidence-based cognitive screening tools, PCPs can improve early detection, facilitate timely referrals, and enhance patient outcomes. Medicare and commercial insurance reimburse cognitive assessments, making them both a clinical necessity and a revenue-generating opportunity for primary care practices.

Take a proactive approach to brain health—integrate cognitive screening into your practice today.

80% of People with Alzheimer's have Insulin Resistance or Type 2 Diabetes

Little to No Workflow

Diabetes Testing Centers™ recognizes the critical importance of cognitive assessments for individuals with diabetes. As part of our comprehensive approach to diabetes care, we offer turnkey cognitive assessments to support healthcare providers in delivering high-quality care. Here's how Diabetes Testing Centers™ provides these assessments:

By providing turnkey cognitive assessments, Diabetes Testing Centers™ empowers healthcare providers to address the cognitive health needs of individuals with diabetes comprehensively. This approach supports the overall well-being of patients and enhances the quality of care in diabetes management.

Poorly Controlled Blood Sugar May Increase the Risk of Developing Alzheimer's

If you're interested in partnering with us, click here to schedule a call and review product offerings and billing insights.